Details:

Alternative Title:
J Acquir Immune Defic Syndr
Personal Author:
Smith, Tyler ; Samandari, Taraz ; Abimbola, Taiwo ; Marston, Barbara ; Sangrujee, Nalinee ;
Smith, Tyler ; Samandari, Taraz ; Abimbola, Taiwo ; Marston, Barbara ; Sangrujee, Nalinee ; Less -
Description:
Objective In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in those with negative TST. We examined the cost-effectiveness of IPT in Botswana, where antiretroviral therapy (ART) is widely available. Design Using a decision-analytic model, we determined the incremental cost-effectiveness of strategies for reducing TB and death in 10,000 PLHIV over 36 months. Methods IPT for 6 months and provision of ART if CD4+ lymphocyte count <250 cells per microliter (2011 Botswana policy) was compared with 6 alternative strategies that varied the use of IPT, TST, and ART for CD4+ count thresholds, including CD4+ <350 and <500 cells per microliter. Results Botswana policy, 2011 was dominated by most other strategies. IPT of 36 months for TST-positive PLHIV with ART for CD4+ <250 cells per microliter resulted in 120 fewer TB cases for an additional cost of $1612 per case averted and resulted in 80 fewer deaths for an additional $2418 per death averted compared with provision of 6-month IPT to TST-positive PLHIV who received ART for CD4+ <250 cells per microliter, the next most effective strategy. Alternative strategies offered lower incremental effectiveness at higher cost. These findings remained consistent in sensitivity analyses. Conclusions A strategy of treating PLHIV who have positive TST with 36-month IPT is more cost effective for reducing both TB and death compared with providing IPT without a TST, providing only 6-month IPT, or expanding ART eligibility without IPT.
Subject:
[+]
Anti-HIV Agents
Antiretroviral Therapy
Antituberculosis Therapy
Article
Botswana
Cost
Cost-Benefit Analysis
Cost-effectiveness
HIV Infection
HIV Infections
Humans
Isoniazid
Tuberculosis
Tuberculosis

Source:
J Acquir Immune Defic Syndr. 70(3):e84-e93 ;
Pubmed ID:
26258564
Pubmed Central ID:
PMC5131632
Document Type:
Journal Article ;
Funding:
CC999999/Intramural CDC HHS/United States ;
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:ef340e0a47e8a3e24ea1c1482f2e1878ed6ac2a5ee2a01837126b8616cbc9e96
File Type:

Supporting Files

• 	nihms830431.nxml	xml
  	nihms830431f1.gif	gif
  	nihms830431f1.jpg	jpeg
  	nihms830431f2.gif	gif
  	nihms830431f2.jpg	jpeg

More +